T1	Participants 62 138	patients with standard-risk disease following haploidentical transplantation
T2	Participants 276 372	patients receiving hematopoietic SCT without ex vivo T-cell-depletion from haploidentical donors
T3	Participants 374 430	224 patients with standard-risk hematological malignancy
